The U.S. Food and Drug Administration has released late Tuesday data on a variety of Covid-19 diagnostic tests in an effort to help doctors, labs and patients evaluate competing products.
There are more than 100 tests for Covid-19 on the market. From the first days of the pandemic, when tests were lacking in the United States, companies rushed to fill the gap with a variety of screening options. This has sometimes caused confusion among consumers and healthcare professionals as to how well they work.
To evaluate the products, the FDA sent developers a standardized panel of samples starting in May, without disclosing how much viral material they had. The agency is doing now The results of this blind test are available, showing in detail how effective more than 55 different screenings are in detecting infection.
Jeff Shuren, director of the FDA’s Center for Instrumental and Radiological Health, said release that the panels provided “valuable information on the comparative effectiveness of different authorized molecular diagnostic tests under the same conditions” and served as a powerful tool for tracking the effectiveness of tests.
The agency said it had passed the panel to 152 molecular test manufacturers as of Sept. 10, although not all data had been returned, some were not interpretable, and other results were still being reviewed. The FDA plans to continue updating the scoreboard.